Last update 23 Nov 2024

CBA-1205

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
CBA 1205, LIV-1205
Target
DLK1
Mechanism
DLK1 inhibitors(Protein delta homolog 1 inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases+ [1]
Active Indication
Hepatocellular CarcinomaLung CancerNeuroblastoma
Inactive Indication-
Originator Organization
LivTech, Inc.LivTech, Inc.Chiome Bioscience, Inc.Chiome Bioscience, Inc.
Active Organization
Chiome Bioscience, Inc.Chiome Bioscience, Inc.
Inactive Organization
ADC Therapeutics SAADC Therapeutics SAKyowa Kirin Co., Ltd.Kyowa Kirin Co., Ltd.
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with CBA-1205
JPRN-JapicCTI-205384 / RecruitingPhase 1
Phase I study of CBA-1205
JPRN-jRCT2080225288 / RecruitingPhase 1
Phase I study of CBA-1205
NCT06636435 / RecruitingPhase 1
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients with Advanced Solid Tumors and Hepatocellular Carcinoma (HCC)
100 Clinical Results associated with CBA-1205
Login to view more data
100 Translational Medicine associated with CBA-1205
Login to view more data
100 Patents (Medical) associated with CBA-1205
Login to view more data
100 Deals associated with CBA-1205
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 1
JP
Chiome Bioscience, Inc.Chiome Bioscience, Inc.
07 Jul 2020
Hepatocellular CarcinomaPhase 1
JP
Chiome Bioscience, Inc.Chiome Bioscience, Inc.
01 Jun 2020
Lung CancerPhase 1
JP
Chiome Bioscience, Inc.Chiome Bioscience, Inc.
-
NeuroblastomaPhase 1
JP
Chiome Bioscience, Inc.Chiome Bioscience, Inc.
-
NeoplasmsDiscovery
JP
Kyowa Kirin Co., Ltd.Kyowa Kirin Co., Ltd.
01 Oct 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
AACR2023
ManualManual
Phase 1
HR-positive/HER2-low Solid Tumors
First line
22
hrzlhzzeac(mwlguurpak) = sepgxvhhnx rqeaguktdv (vihelckfnk )
View more
Positive
14 Apr 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free